Xuchao Peng1, Lisha Hou1, Yanli Zhao1, Taiping Lin1, Hui Wang1,2, Langli Gao3,4,5, Jirong Yue1,2. 1. National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan Province, China. 2. Department of Geriatrics, West China Hospital, Sichuan University, Chengdu, China. 3. National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu, 610041, Sichuan Province, China. gaolangli@126.com. 4. Department of Geriatrics, West China Hospital, Sichuan University, Chengdu, China. gaolangli@126.com. 5. West China School of Nursing, Sichuan University, Chengdu, China. gaolangli@126.com.
Abstract
PURPOSE: We conducted a systematic review to evaluate the relationship between total testosterone (TT), free testosterone (fT), or sex hormone-binding globulin (SHBG) and frailty in older adults. METHODS: We systematically searched nine databases (e.g. MEDLINE, Embase, ACP Journal Club, and the Cochrane library et al.) for papers on frailty and androgen levels published up to October 10, 2021. We calculated the odds ratio (OR) for the relationship between testosterone level and frailty by performing meta-analysis. RESULTS: The search strategy yielded 311 hits in all databases combined. Eleven (seven cross-sectional studies and four cohort studies) met the inclusion criteria for meta-analysis. Among cross-sectional studies, meta-analysis revealed a significant association between TT and frailty in men (OR = 1.37 [95% CI 1.09, 1.72]) not women (OR = 1.06 [0.84, 1.34]). The fT was also significantly association with frailty in men (OR = 1.55 [1.06, 2.25] not women (OR = 1.35 [0.91, 2.01]). Cohort studies showed the same result in TT (OR = 1.09 [1.02, 1.18]) and fT (OR = 1.15 [1.02, 1.30]) for men. We did not find a significant association between SHBG and frailty. CONCLUSION: The findings of this systematic review and meta-analysis suggest that TT and fT were significantly associated with frailty in older men but not women.
PURPOSE: We conducted a systematic review to evaluate the relationship between total testosterone (TT), free testosterone (fT), or sex hormone-binding globulin (SHBG) and frailty in older adults. METHODS: We systematically searched nine databases (e.g. MEDLINE, Embase, ACP Journal Club, and the Cochrane library et al.) for papers on frailty and androgen levels published up to October 10, 2021. We calculated the odds ratio (OR) for the relationship between testosterone level and frailty by performing meta-analysis. RESULTS: The search strategy yielded 311 hits in all databases combined. Eleven (seven cross-sectional studies and four cohort studies) met the inclusion criteria for meta-analysis. Among cross-sectional studies, meta-analysis revealed a significant association between TT and frailty in men (OR = 1.37 [95% CI 1.09, 1.72]) not women (OR = 1.06 [0.84, 1.34]). The fT was also significantly association with frailty in men (OR = 1.55 [1.06, 2.25] not women (OR = 1.35 [0.91, 2.01]). Cohort studies showed the same result in TT (OR = 1.09 [1.02, 1.18]) and fT (OR = 1.15 [1.02, 1.30]) for men. We did not find a significant association between SHBG and frailty. CONCLUSION: The findings of this systematic review and meta-analysis suggest that TT and fT were significantly associated with frailty in older men but not women.
Authors: Shalender Bhasin; Glenn R Cunningham; Frances J Hayes; Alvin M Matsumoto; Peter J Snyder; Ronald S Swerdloff; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2010-06 Impact factor: 5.958
Authors: Emiel O Hoogendijk; Jonathan Afilalo; Kristine E Ensrud; Paul Kowal; Graziano Onder; Linda P Fried Journal: Lancet Date: 2019-10-12 Impact factor: 79.321
Authors: Ángel García; Víctor Toro-Román; Jesús Siquier-Coll; Ignacio Bartolomé; Diego Muñoz; Marcos Maynar-Mariño Journal: Int J Environ Res Public Health Date: 2022-05-16 Impact factor: 4.614
Authors: A M Isidori; A Aversa; A Calogero; A Ferlin; S Francavilla; F Lanfranco; R Pivonello; V Rochira; G Corona; M Maggi Journal: J Endocrinol Invest Date: 2022-08-26 Impact factor: 5.467